Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$10.91 USD
+0.36 (3.41%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $10.93 +0.02 (0.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Earnings News For PLRX
-
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
-
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
-
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates
-
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
-
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
-
Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates
-
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
-
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?
-
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates
-
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates
-
Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates